CD1A
- Known as:
- CD1A
- Catalog number:
- ANT-206
- Product Quantity:
- 500µg
- Category:
- -
- Supplier:
- Prospecbio
- Gene target:
- CD1A
Related genes to: CD1A
- Gene:
- CD1A NIH gene
- Name:
- CD1a molecule
- Previous symbol:
- CD1
- Synonyms:
- -
- Chromosome:
- 1q23.1
- Locus Type:
- gene with protein product
- Date approved:
- 1988-05-11
- Date modifiied:
- 2017-07-07
Related products to: CD1A
Related articles to: CD1A
- A major long-term complication following allogeneic hematopoietic cell transplantation (HCT) is graft-versus-host disease (GVHD). Oral chronic GVHD (cGVHD) is common and affects the mucosa with diagnostic lichenoid-like manifestations. Distinctive features such as hyposalivation and inflammatory histopathology of the salivary glands have been associated with both transplant regimen and GVHD. We retrospectively explored the association of hyposalivation and minor salivary gland (MSG) histopathology with the establishment and progression of GVHD. - Source: PubMed
Publication date: 2026/05/08
Tollemar VictorHilmer AnnaIvinger CamillaSugars Rachael V - Langerhans cell histiocytosis (LCH) is a rare clonal histiocytic neoplasm that is uncommon in adults and may be diagnostically challenging because of its heterogeneous clinical presentation. We report a case of a 55-year-old male who presented with persistent right ankle pain and multifocal lytic lesions involving the distal tibia, fibula, talus, calcaneus, and cuboid. His medical history was notable for a pituitary lesion with central diabetes insipidus diagnosed two years earlier. Open biopsy of the tibia demonstrated a mixed infiltrate containing characteristic Langerhans cells with grooved nuclei and numerous eosinophils. Immunohistochemistry showed strong positivity for CD1a, S100, and langerin (CD207), confirming LCH. Staging studies revealed pituitary involvement and mild radiologic splenomegaly, without evidence of hematopoietic or hepatic risk-organ dysfunction. Retrospective molecular testing on stored tissue was negative for BRAF V600E. The patient was treated with vinblastine and prednisolone, along with desmopressin and somatotropin replacement. Zoledronic acid was added for osseous disease. Over 70 months of follow-up, the patient achieved durable clinical and radiologic disease control, with pain improving from 7/10 to 1/10 and no evidence of relapse at last contact. Treatment-related toxicity was limited to mild peripheral neuropathy. This case highlights an unusual presentation of adult LCH with distal lower-extremity and tarsal bone involvement, as well as hypothalamic-pituitary disease preceding osseous diagnosis by two years. It underscores the importance of considering LCH in adults with unexplained multifocal lytic bone lesions and endocrine dysfunction, and it demonstrates that durable disease control can be achieved with systemic therapy. - Source: PubMed
Publication date: 2026/04/19
Hacker PhilippBenignus ChristianFrauenfeld LeonieTraub Frank - Pulmonary Langerhans cell histiocytosis (PLCH) is an uncommon myeloid disorder of the lung characterized by the accumulation of Langerhans-like cells within the pulmonary parenchyma. On imaging, it typically presents as nodular or cystic lesions and is closely associated with cigarette smoking. Although PLCH can occur in both children and adults, it is more frequently observed in younger smokers and is relatively rare in elderly individuals. In most cases, the disease follows a slow and sometimes self-limiting course, and systemic therapy is not routinely required. However, radiologic differentiation from malignant ground-glass nodules may be challenging. The development of PLCH after lung adenocarcinoma surgery is rare. Here, we report the case of a 72-year-old woman with lung adenocarcinoma. Following resection of a right lung nodule, molecular testing identified an EGFR exon 19 deletion, and icotinib was subsequently administered for contralateral ground-glass nodules. During postoperative follow-up, new lesions were detected in the rib adjacent to the surgical field as well as in the lung, raising concern for possible bone metastasis on imaging. Percutaneous biopsy with immunohistochemical analysis demonstrated positivity for CD1a, Langerin, and S-100, while lung adenocarcinoma-associated markers, including CK7, TTF-1, and Napsin A, were negative, supporting a diagnosis of PLCH. The next generation sequencing found BRAF V600E mutation in PLCH lesions. After symptomatic treatment and long-term follow-up, the lesions gradually improved and partially disappeared. Looking back on the previously reported cases, it is not common for PLCH and lung adenocarcinoma to coexist. In published reports, these two conditions generally have different driving gene changes, and their potential biological relationship is still unclear. This case shows that when new lesions are found after lung cancer surgery, besides tumor recurrence, other diagnoses, namely PLCH, should be considered, and the diagnosis should be confirmed by histopathological examination. - Source: PubMed
Publication date: 2026/04/25
Liu YihaoDuan ZhixuanLiu MinghuiZhang HongbingLi YongwenWang MinZhang HaolingChen JunZhao Honglin - We report the first documented case of isolated episcleral ALK-positive histiocytosis (ALK+H) in an adult. A 36-year-old woman presented with an episcleral nodule clinically mimicking nodular scleritis. Excisional biopsy revealed sheets of foamy CD68+/CD163+ histiocytes with Touton-type giant cells. Immunohistochemistry demonstrated strong cytoplasmic ALK1 expression with negative CD1a and BRAF V600E, and fluorescence in situ hybridization confirmed ALK gene rearrangement in 60% of nuclei. Whole-body PET-CT identified a suspicious inguinal node, subsequently proven reactive on biopsy. Following excision, symptomatic local recurrence developed within 3 months, confirmed by orbital MRI. Alectinib 600 mg twice daily was commenced, with symptomatic improvement after 2 months. This case expands the anatomic spectrum of ALK+H to the ocular surface, highlighting that routine ALK1 screening of atypical histiocytic infiltrates is essential for accurate diagnosis and access to targeted therapy. - Source: PubMed
Publication date: 2026/05/19
Abraham Latha KPaul MobinPauly MarianT LekhaJohn Neetha Soma - Langerhans cells express the nonpolymorphic antigen-presenting molecule CD1a, positioning them as contributors to host immunity against in human leprosy. CD1a was originally shown to present non-canonical lipopeptide antigens such as dideoxymycobactin and chemically diverse hydrophobic ligands. Here, we generated CD4⁺ T cell lines from leprosy lesions that recognized in a CD1a-restricted manner. Unexpectedly, antigen recognition was protease-sensitive, prompting biochemical purification that identified two microbial protein antigens: LppX, a 25-kDa lipoglycoprotein, and Ag85A, a 30-kDa secreted protein with no known lipid modification. Recombinant proteins activated the corresponding T cell lines in a CD1a-dependent manner. Epitope mapping identified 12-mer peptides that fully reconstituted antigenicity, were conserved between and , and elicited robust, dose-dependent IFN-γ production and T cell proliferation, establishing that DNA-encoded, ribosomally translated peptides serve as CD1a-restricted cognate antigens. Biochemical analyses showed peptide binding to CD1a, supported by isoelectric focusing and surface plasmon resonance ( ∼75 μM for Ag85A). CD1a-peptide tetramers specifically stained cognate T cells, soluble CD1a was sufficient to present peptide antigen, and transfer of the LppX-specific TCR into naïve T cells restored antigen responsiveness. Using CD1a-peptide tetramers, we identified antigen-specific T cells enriched in patients undergoing reversal reactions compared with patients with lepromatous leprosy and healthy donors. The CD1a-restricted T cell lines secreted IFN-γ and IL-26, cytokines with established antimicrobial activity. Together, these findings demonstrate that CD1a can present canonical microbial peptides as part of a cell-mediated immune response in leprosy, extending the known spectrum of CD1a ligands. Because CD1a is nonpolymorphic and presents antigens to antimicrobial T cells, CD1a-peptide complexes may provide a broadly applicable platform for studying, detecting, and potentially targeting mycobacterial immunity. - Source: PubMed
Publication date: 2026/05/09
de Andrade Silva Bruno Jorgede Jong AnnemiekeFischbacher Linda AMarques Maria Angela MLegaspi AnnalizaShahine AdamKollmorgen JadeSieling Peter AChoi AaronKim Hee JinMatos E Silva Carlos AdrianoWebb Kristofor JBradshaw JasonBrennan Patrick JMarusina AlinaTran Khiem ASarno Euzenir NunesPinheiro Roberta OlmoZajonc Dirk MMoody D BranchNiazi Kayvan RMaverakis EmanualSette AlessandroRossjohn JamieOchoa Maria TBelisle John TModlin Robert L